Non-severe haemophilia: Is it benign? - Insights from the PROBE study.


Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 12 03 2020
revised: 15 06 2020
accepted: 22 06 2020
pubmed: 2 9 2020
medline: 25 9 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

There are limited data on the impact of haemophilia on health status and health-related quality of life (HRQL) in people with non-severe (mild and moderate) haemophilia. To evaluate the health status of people living with mild or moderate haemophilia. Data on respondents with no bleeding disorder (NoBD), mild and moderate haemophilia patients were drawn from the PROBE study. Respondents were enrolled using network patient organizations. This analysis was performed as a cross-sectional study. Primary outcomes were reported bleeding, acute and chronic pain, activities of daily living and HRQL. A total of 862 respondents with NoBD (n = 173), mild (n = 102) and moderate (n = 134) haemophilia were eligible, with a median age of 33, 42 and 43, respectively. In relation to haemophilia-related sequalae, 53% of male and 29% of female patients with mild and 83% of males with moderate haemophilia had more than 2-3 bleeds in the last 12 months. Reporting of acute and chronic pain is less in those with NoBD compared to the mild and moderate cohorts for both genders. Multivariate analysis demonstrates significant reductions in quality of life using VAS, EQ-5D-5L and PROBE for males with mild and moderate haemophilia (P ≤ .001) with only PROBE indicating a significant reduction for females with mild (P = .002). People affected by mild or moderate haemophilia report a significant HRQL impact due to haemophilia-related bleeding. Future research is needed to identify the optimal care management of patients with mild and moderate haemophilia.

Identifiants

pubmed: 32870546
doi: 10.1111/hae.14105
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-24

Subventions

Organisme : Bayer
Organisme : Takeda
Organisme : Sobi
Organisme : Roche
Organisme : Sanofi
Organisme : Novo Nordisk
Organisme : CSL Behring

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Makris M, Oldenburg J, Mauser-Bunschoten EP, et al. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(12):2530-2533.
Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-1809.
Reitter S, Waldhoer T, Vutuc C, Lechner K, Pabinger I. Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006. Haemophilia. 2009;15(4):888-893.
Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med. 1995;123(11):823-827.
Skinner MW, Chai-Adisaksopha C, Curtis R, et al. The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot Feasibility Stud. 2018;4:58.
Chai-Adisaksopha C, Skinner MW, Curtis R, et al. Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open. 2018;8(8):e021900.
Chai-Adisaksopha C, Skinner MW, Curtis R, et al. Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia. 2019;25(1):75-83.
Chai-Adisaksopha C, Skinner MW, Curtis R, et al. Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia. 2019;25(3):365-372.
EuroQol G. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
Peyvandi F, Tavakkoli F, Frame D, et al. Burden of mild haemophilia A: systematic literature review. Haemophilia. 2019;25(5):755-763.
Walsh M, Macgregor D, Stuckless S, Barrett B, Kawaja M, Scully MF. Health-related quality of life in a cohort of adult patients with mild hemophilia A. J Thromb Haemost. 2008;6(5):755-761.
Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540.

Auteurs

Chatree Chai-Adisaksopha (C)

Department of Medicine, McMaster University, Hamilton, ON, Canada.
Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand.

Declan Noone (D)

Health Decisions Consultants, Dublin, Ireland.
European Haemophilia Consortium, Brussels, Belgium.

Randall Curtis (R)

Factor VIII Computing, Berkeley, CA, USA.

Neil Frick (N)

National Hemophilia Foundation, New York, NY, USA.

Michael B Nichol (MB)

Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, USA.

Federico Germini (F)

Department of Medicine, McMaster University, Hamilton, ON, Canada.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.

Brian O'Mahony (B)

Trinity College Dublin, Dublin, Ireland.
Irish Haemophilia Society, Dublin, Ireland.

David Page (D)

Canadian Hemophilia Society, Montreal, QC, Canada.

Jeffrey S Stonebraker (JS)

Poole College of Management, North Carolina State University, Raleigh, NC, USA.

Mark W Skinner (MW)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Institute for Policy Advancement Ltd, Washington, DC, USA.

Alfonso Iorio (A)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
McMaster-Bayer Endowed Research Chair in Clinical Epidemiology of Congenital Bleeding Disorders, Department of Medicine, McMaster, Hamilton, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH